RENEE MONTAGNE, HOST:
Today in Your Health - most of the time, biomedical research advances in tiny increments. Still, every once in a while, a researcher makes a discovery that leads to a complete change in medical practice. As part of his series Joe's Big Idea, NPR's Joe Palca introduces us to a scientist who had a fundamental insight that ultimately saved the lives of millions of premature babies.
JOE PALCA, BYLINE: In 1950, the U.S. Army sent a young doctor by the name of John Clements to the medical division of the Army Chemical Center in Edgewood, Md. Clements was interested in doing research in biochemistry. His commanding officer was of a different mind.
JOHN CLEMENTS: We don't need any biochemists. You are going be a physiologist. And I became a physiologist because the Army said so.
PALCA: At the time, the Army was worried about the Soviet Union using chemical weapons.
CLEMENTS: My assignment was to find out how nerve gases worked on the lungs.
PALCA: So he set out to learn all he could about the lungs. Now, the lungs are made up of thin sacs called alveoli. Think of them as tiny balloons. Oxygen enters the bloodstream through the outer membranes of these sacs. When these sacs inflate, there's more surface area for oxygen to cross into the blood. But how much surface area is there in the normal lung? It's not an easy question to answer. One group of researchers made an estimate based on what they saw through the microscope. They calculated the surface area was huge, maybe the size of a football field if you spread it all out. But others tried estimating the size based on the energy needed to inflate the sacs. They came up with a much smaller area.
CLEMENTS: That huge discrepancy between two supposedly correct methods bothered me.
PALCA: Then in 1953, Clements discovered a way to explain the discrepancy. He said, what if there were some substance made in the lung that made it easier to inflate the alveoli? A few years later, Clements and others found that substance. Not long after that, another team of researchers showed it played a role in human lung disease.
CLEMENTS: At that point, the research - to use the trite term - exploded.
PALCA: Clements was doing basic research, not trying to cure a disease - but the work did cure a disease. Turns out that premature babies can't make that substance called lung surfactant. So without it, they frequently died from something called respiratory distress syndrome, or RDS. Sam Hawgood is chancellor of the University of California, San Francisco, but once upon a time, he worked in Clements' lab. Hawgood says there's now a synthetic form of surfactant for treating premature babies.
SAM HAWGOOD: It took 40 years from the initial discovery in the early '50s to the approval of the FDA in the 1990s, and all of us would like to compress that timeline. But if you think that we had no idea that this substance even existed or was needed in the '50s to an actual drug four decades later, it's pretty remarkable.
PALCA: What's also remarkable is John Clements himself. Today, Clements has a lab at the University of California, San Francisco. He's now 92, and he still goes in every day. He's justifiably proud of what his work has meant for infants with respiratory distress syndrome.
CLEMENTS: When we began this work back in the 1950s, the mortality from RDS was above 90 percent. Today, that mortality is 5 percent or less.
PALCA: That's about as big an improvement as you could possibly hope for in medicine. I asked Clements why was he still coming into the lab. I mean, surely he'd done enough at this point in his research career. He said the answer is there's always the chance that a new day will bring a new scientific insight.
CLEMENTS: The thrill of that is the best thing there is. Well, at my age, I'd put it even higher than sex (laughter). But it's a big, big thrill when you think you've made a discovery, found an idea that no one else has had. That's as good as it gets.
PALCA: Well, sounds good to me. Joe Palca, NPR News.
NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.